Abstract: A composition for film formation containing a polycyclic polyphenolic resin having repeating units derived from at least one monomer selected from the group consisting of aromatic hydroxy compounds represented by the formulas (1-0), (1A), and (1B), wherein the repeating units are linked by a direct bond between aromatic rings:

Abstract: An object of the present invention is to provide a resist underlayer film forming composition for lithography that has features of having excellent smoothing performance on an uneven substrate, good embedding performance into a fine hole pattern, and a smoothed wafer surface after film formation, and the like. The object can be achieved by an underlayer film forming composition for lithography containing a compound having a protecting group.

Abstract: The polyester resin composition according to the present invention contains a polyester resin (A) containing, as a diol unit, a unit derived from diol having a cyclic acetal skeleton, and as a dicarboxylic acid unit, a unit derived from dicarboxylic acid having a naphthalene skeleton, and a polyester resin (B) not having a cyclic acetal skeleton; and satisfies following (1) and (2): (1) a refractive index difference between the polyester resin (A) and the polyester resin (B) is 0.005 or less, the refractive index being measured with sodium D radiation as a light source; (2) a glass transition temperature difference between the polyester resin (A) and the polyester resin (B) is 35° C. or less.

Abstract: One embodiment of the present invention provides: a thermoplastic resin composition which contains a polycarbonate resin and a polyester resin that contains a diol unit having a cyclic acetal skeleton, and wherein the polyester resin contains specific amounts of phosphorus atoms and titanium atoms and the weight ratio of the phosphorus atoms to the titanium atoms is within a specific range; and a molded body which uses this thermoplastic resin composition.

Abstract: This thermoplastic resin composition (D) contains a polycarbonate resin (A), a polyester resin (B) which comprises diol structural units and dicarboxylic acid structural units in which the ratio of diol structural units having a cyclic acetal skeleton to all diol structural units is 20 to 60 mol %, and a polyester resin (C) other than the polyester resin (B), wherein the ratio of the polycarbonate resin (A) to the total of the polycarbonate resin (A), the polyester resin (B) and the polyester resin (C) is 15 to 98 wt %, the ratio of the polyester resin (B) is 1 to 80 wt %, and the ratio of the polyester resin (C) is 1 to 60 wt %; further provided is a sheet using said thermoplastic resin.

Abstract: A resin-made multilayer molding includes two or more resin layers, at least one resin layer is configured from a mixed resin (B) containing, at a ratio (C)/(D)=99/1 to 10/90 by weight, a polyamide resin (C) obtained by polymerizing a diamine component containing 70 mol % or more of m-xylylenediamine and a dicarboxylic acid component containing 70 mol % or more of adipic acid, and a polyester resin (D) containing a dicarboxylic acid unit and a diol unit, 1-80 mol % of the diol unit having a cyclic acetal skeleton; and at least one resin layer in contact with a layer configured from the mixed resin (B) is configured from a resin containing 70 wt % or more of a thermoplastic polyester resin (A) obtained by polymerizing a dicarboxylic acid component containing 80 mol % or more of terephthalic acid and a diol component containing 80 mol % or more of ethylene glycol.

Abstract: The polyester resin composition according to the present invention contains a polyester resin (A) containing, as a diol unit, a unit derived from diol having a cyclic acetal skeleton, and as a dicarboxylic acid unit, a unit derived from dicarboxylic acid having a naphthalene skeleton, and a polyester resin (B) not having a cyclic acetal skeleton; and satisfies following (1) and (2): (1) a refractive index difference between the polyester resin (A) and the polyester resin (B) is 0.005 or less, the refractive index being measured with sodium D radiation as a light source; (2) a glass transition temperature difference between the polyester resin (A) and the polyester resin (B) is 35° C. or less.

Abstract: This thermoplastic resin composition (D) contains a polycarbonate resin (A), a polyester resin (B) which comprises diol structural units and dicarboxylic acid structural units in which the ratio of diol structural units having a cyclic acetal skeleton to all diol structural units is 20 to 60 mol %, and a polyester resin (C) other than the polyester resin (B), wherein the ratio of the polycarbonate resin (A) to the total of the polycarbonate resin (A), the polyester resin (B) and the polyester resin (C) is 15 to 98 wt %, the ratio of the polyester resin (B) is 1 to 80 wt %, and the ratio of the polyester resin (C) is 1 to 60 wt %; further provided is a sheet using said thermoplastic resin.

Abstract: The present invention provides a polyester resin composition including, a polyester resin (A) including a dicarboxylic acid unit and a diol unit, 1 to 60 mol % of the diol unit being a diol unit having a cyclic acetal skeleton; a phosphorus compound (B) represented by the following general formula (1); and a basic compound (C), wherein, based on 100 parts by weight of the polyester resin (A), the phosphorus compound (B) is in an amount of 0.005 to 2 parts by weight and the basic compound (C) is in an amount of 0 to 2 parts by weight, and a method for producing the polyester resin composition: (wherein R1, R2, R3 and R4 each independently represent an aryl group, X represents a divalent group derived from an aromatic dihydroxy compound having 6 to 15 carbon atoms, and n is an integer of 1 to 5.

Abstract: 3,4-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,4-substituted piperidine compound, and/or a method of treatment comprising administering a 3,4substituted piperidine compound, a method for the manufacture of a 3,4-substituted piperidine compound, and novel intermediates and partial steps for their synthesis are disclosed. The 3,4-disubstituted piperidine compounds have the formula (I), wherein the symbols have the meanings defined in the specification.

Abstract: The present invention relates to the use of a 2-cyanopyrimidine compound of the formula wherein R1, R2, R3 and X are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in tautomeric form, as an inhibitor of the activity of cathepsin S.

Abstract: The present invention relates to the use of a 2-cyanopyrimidine compound of the formula wherein R1, R2, R3 and X are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in tautomeric form, as an inhibitor of the activity of cathepsin S.

Abstract: The invention relates to pyrrolo pyrimidines of formula (I), wherein Y represents —(CH2)t—O— or —(CH2)r—S—, p is 1 or 2, r is 1, 2 or 3, t is 1, 2 or 3, or Y is —(CH2)j— or —CH?CH—, j is 1 or 2; p is 1 or 2, or Y is —(CH2)f—, f is 1 or 2, p is 1, and the further radicals and symbols have the meaning as defined herein; their preparation, their use as pharmaceuticals, pharmaceutical compositions containing them, the use of such a compound for the manufacture of a pharmaceutical preparation for the treatment of neuropathic pain and to a method for the treatment of such a disease in animals, especially in humans.